Roy Gulick to Humans
This is a "connection" page, showing publications Roy Gulick has written about Humans.
Connection Strength
0.072
-
The Uncertain Role of Corticosteroids in the Treatment of COVID-19. JAMA Intern Med. 2021 01 01; 181(1):140.
Score: 0.007
-
Prioritizing clinical research studies during the COVID-19 pandemic: lessons from New York City. J Clin Invest. 2020 09 01; 130(9):4522-4524.
Score: 0.007
-
Safety, tolerability, and clinical outcomes of hydroxychloroquine for hospitalized patients with coronavirus 2019 disease. PLoS One. 2020; 15(7):e0236778.
Score: 0.007
-
New HIV drugs: 2018 and beyond. Curr Opin HIV AIDS. 2018 07; 13(4):291-293.
Score: 0.006
-
Investigational Antiretroviral Drugs: What is Coming Down the Pipeline. Top Antivir Med. 2018 Apr; 25(4):127-132.
Score: 0.006
-
Safety and Tolerability of Maraviroc-Containing Regimens to Prevent HIV Infection in Women: A Phase 2 Randomized Trial. Ann Intern Med. 2017 Sep 19; 167(6):384-393.
Score: 0.006
-
Antiretroviral treatment 2010: progress and controversies. J Acquir Immune Defic Syndr. 2010 Dec; 55 Suppl 1:S43-8.
Score: 0.004
-
Durability of response to treatment among antiretroviral-experienced subjects: 48-week results from AIDS Clinical Trials Group Protocol 359. J Infect Dis. 2002 Sep 01; 186(5):626-33.
Score: 0.002
-
Developing Treatment Guidelines During a Pandemic Health Crisis: Lessons Learned From COVID-19. Ann Intern Med. 2021 08; 174(8):1151-1158.
Score: 0.002
-
Blood component utilization in COVID-19 patients in New York City: Transfusions do not follow the curve. Transfusion. 2021 03; 61(3):692-698.
Score: 0.002
-
Convalescent Plasma for the Treatment of COVID-19: Perspectives of the National Institutes of Health COVID-19 Treatment Guidelines Panel. Ann Intern Med. 2021 01; 174(1):93-95.
Score: 0.002
-
Obesity and COVID-19 in New York City: A Retrospective Cohort Study. Ann Intern Med. 2020 11 17; 173(10):855-858.
Score: 0.002
-
Severe Covid-19. N Engl J Med. 2020 Dec 17; 383(25):2451-2460.
Score: 0.002
-
Clinical Characteristics of Covid-19 in New York City. N Engl J Med. 2020 06 11; 382(24):2372-2374.
Score: 0.002
-
The Control of HIV After Antiretroviral Medication Pause (CHAMP) Study: Posttreatment Controllers Identified From 14 Clinical Studies. J Infect Dis. 2018 11 05; 218(12):1954-1963.
Score: 0.002
-
Combination therapy with anti-HIV-1 antibodies maintains viral suppression. Nature. 2018 09; 561(7724):479-484.
Score: 0.002
-
Safety and antiviral activity of combination HIV-1 broadly neutralizing antibodies in viremic individuals. Nat Med. 2018 11; 24(11):1701-1707.
Score: 0.002
-
Relationship between latent and rebound viruses in a clinical trial of anti-HIV-1 antibody 3BNC117. J Exp Med. 2018 09 03; 215(9):2311-2324.
Score: 0.002
-
Brain neurotransmitter transporter/receptor genomics and efavirenz central nervous system adverse events. Pharmacogenet Genomics. 2018 07; 28(7):179-187.
Score: 0.002
-
Genetic Variation of the Kinases That Phosphorylate Tenofovir and Emtricitabine in Peripheral Blood Mononuclear Cells. AIDS Res Hum Retroviruses. 2018 05; 34(5):421-429.
Score: 0.002
-
A Conversation Among the IAS-USA Board of Directors: Hot Topics and Emerging Data in HIV Research and Care. Top Antivir Med. 2017 Dec/Jan; 24(4):142-151.
Score: 0.001
-
Antibody 10-1074 suppresses viremia in HIV-1-infected individuals. Nat Med. 2017 Feb; 23(2):185-191.
Score: 0.001
-
Novel clinical trial designs for the development of new antiretroviral agents. AIDS. 2012 May 15; 26(8):899-907.
Score: 0.001
-
Vicriviroc resistance decay and relative replicative fitness in HIV-1 clinical isolates under sequential drug selection pressures. J Virol. 2012 Jun; 86(12):6416-26.
Score: 0.001
-
Lymphoma diagnosis and plasma Epstein-Barr virus load during vicriviroc therapy: results of the AIDS Clinical Trials Group A5211. Clin Infect Dis. 2009 Mar 01; 48(5):642-9.
Score: 0.001